ALCOX Nicox SA

Press Release

Nicox Announces Presentation of Data on NCX 470 at the 2024 American Glaucoma Society Annual Meeting

March 5, 2024 – release at 7:30 am CETSophia Antipolis, France

Nicox SA (Euronext Growth Paris: FR0013018124, ALCOX), an international ophthalmology company, today provided details of poster presentations highlighting data on NCX 470 at the 2024 American Glaucoma Society (AGS) Annual Meeting, one of the key scientific events in vision research, which was held on February 29th to March 3rd, 2024 in Huntington Beach, CA, United States.

“We are proud to have presented data on our lead product candidate NCX 470 in glaucoma to the scientific community at the prestigious AGS meeting. The data provide further evidence of the efficacy of NCX 470, and its robust intraocular pressure lowering effect, reinforcing the positive results we have seen in the first Phase 3 trial, Mont Blanc. We are looking forward to continuing to progress NCX 470 in the second Phase 3 trial, Denali, and moving this innovative product towards market,” said Doug Hubatsch, Chief Scientific Officer of Nicox.

Details of the presentations are as follows:

Poster title: Intraocular Pressure Reduction with NCX 470 versus Latanoprost Across the Spectrum of Baseline Intraocular Pressures

An analysis of Intraocular pressure (IOP) reduction by baseline IOPs demonstrated that in patients with baseline pressures ≤ 28 mmHg, NCX 470 was numerically better at all, and statistical superior at 5/6 timepoints at lowering IOP vs. latanoprost, the current standard of care. Furthermore, NCX 470 provided consistent IOP reduction across the spectrum of baseline IOPs while latanoprost IOP reduction was baseline IOP-dependent.

Poster title: Intraocular Pressure Reduction with NCX 470 versus Latanoprost In Previously Treated Versus Treatment-Naïve Patients

In a pre-planned analysis, we tested whether being on previous IOP lowering medications had an impact on the IOP lowering of NCX 470. Previously treated subjects had greater IOP lowering vs. latanoprost at all timepoints but not by a clinically significant margin. Differences in IOP lowering between treatments were minimal in previously untreated patients. Whether previously treated or treatment naïve-should not impact the selection of NCX 470 versus latanoprost in the treatment of OAG or OHT.

The posters are available on Nicox’s website in the section Publications.

About NCX 470

NCX 470, a novel NO-donating bimatoprost eye drop, is currently in Phase 3 clinical development for the lowering of IOP in patients with open-angle glaucoma or ocular hypertension. Results of Mont Blanc, the first of the two Phase 3 clinical trials, have been announced in October 2022. The second Phase 3 clinical trial, Denali, is currently ongoing, and the results are expected in 2025.About Nicox

Nicox SA is an international ophthalmology company developing innovative solutions to help maintain vision and improve ocular health. Nicox’s lead program in clinical development is NCX 470, a novel nitric oxide-donating bimatoprost eye drop, for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Nicox generates revenue from VYZULTA® in glaucoma, licensed exclusively worldwide to Bausch + Lomb, and ZERVIATE® in allergic conjunctivitis, licensed in multiple geographies, including to Harrow, Inc. in the U.S., and Ocumension Therapeutics in the Chinese and in the majority of Southeast Asian markets.

Nicox, headquartered in Sophia Antipolis, France, is listed on Euronext Growth Paris (Ticker symbol: ALCOX) and is part of the CAC Healthcare index.

For more information www.nicox.com.

Analyst coverage

Bryan, Garnier & Co         Eric Yoo        Paris, FranceH.C. Wainwright & Co        Yi Chen        New York, U.S.

The views expressed by analysts in their coverage of Nicox are those of the author and do not reflect the views of Nicox. Additionally, the information contained in their reports may not be correct or current. Nicox disavows any obligation to correct or to update the information contained in analyst reports.Contacts

Forward-Looking Statements

The information contained in this document may be modified without prior notice. This information includes forward-looking statements. Such forward-looking statements are not guarantees of future performance. These statements are based on current expectations or beliefs of the management of Nicox S.A. and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Nicox S.A. and its affiliates, directors, officers, employees, advisers or agents, do not undertake, nor do they have any obligation, to provide updates or to revise any forward-looking statements.

Risks factors which are likely to have a material effect on Nicox’s business are presented in section 2.7 of the “Rapport Annuel 2022” and in section 4 of the “Rapport semestriel financier et d’activité 2023” which are available on Nicox’s website (www.nicox.com).

Nicox S.A.Sundesk Sophia Antipolis, Bâtiment C, Emerald Square, Rue Evariste Galois, 06410 Biot, FranceT +33 (0)4 97 24 53 00

Attachment

• EN_AGS 2024 posters _20240305_F

Nicox (EU:ALCOX)
Gráfica de Acción Histórica
De Oct 2024 a Nov 2024

Nicox (EU:ALCOX)
Gráfica de Acción Histórica
De Nov 2023 a Nov 2024